Xtl Biopharma ADR (XTLB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,027 | -1,782 | -1,348 | 435 | -2,954 |
| Depreciation Amortization | 199 | N/A | 1 | 1 | 1 |
| Income taxes - deferred | -130 | N/A | N/A | N/A | N/A |
| Accounts receivable | 39 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | N/A | -44 | -23 | 22 |
| Other Working Capital | 189 | 64 | -19 | -54 | 45 |
| Other Operating Activity | -888 | 1,011 | 509 | -1,408 | 2,036 |
| Operating Cash Flow | $-1,618 | $-707 | $-901 | $-1,049 | $-850 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | N/A | N/A | 33 |
| PPE Investments | -54 | N/A | N/A | N/A | -1 |
| Net Acquisitions | -410 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -380 | 41 | 36 | 8 | 0 |
| Investing Cash Flow | $-844 | $41 | $36 | $8 | $32 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | -13 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 1,460 | N/A | N/A | 385 | N/A |
| Financing Cash Flow | $1,447 | $N/A | $N/A | $385 | $N/A |
| Exchange Rate Effect | -15 | -27 | -10 | -6 | -6 |
| Beginning Cash Position | 1,401 | 2,094 | 2,969 | 3,631 | 4,455 |
| End Cash Position | 371 | 1,401 | 2,094 | 2,969 | 3,631 |
| Net Cash Flow | $-1,030 | $-693 | $-875 | $-662 | $-824 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,618 | -707 | -901 | -1,049 | -850 |
| Capital Expenditure | -54 | N/A | N/A | N/A | -1 |
| Free Cash Flow | -1,672 | -707 | -901 | -1,049 | -851 |